Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Early study supports freezing for prostate cancer

This article was originally published in Clinica

Executive Summary

Cryoablation is an effective treatment for prostate cancer, reduces complications and costs less than either radiotherapy or surgery. Preliminary data from 310 patients show only 10% recurrence, although follow-up ranges from only three months to two years, Dr Duke Bahn of the Crittenton Hospital, Rochester, Minnesota, told the American Roentgen Ray Society's annual meeting in Washington last month. Dr Bahn says complications are infrequent and incontinence is only 1% compared with about 30% in surgery patients.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT091826

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel